Ruchi Bhatt, DO, discusses the investigation of trastuzumab deruxtecan in HER2-low breast cancer.
Ruchi Bhatt, DO
Advertisement
Articles by Ruchi Bhatt, DO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
NCCN Guidelines Recognize MammaPrint/BluePrint for Determining Anthracycline Benefit in Breast Cancer
3
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5